The EMERALD trial evaluated elacestrant, an oral SERD, as a potential new standard for patients with ER+/HER2– advanced breast cancer resistant to prior endocrine therapies.
Beyond the Primary Endpoint: Diving Deeper Into the EMERALD Trial
As resistance to endocrine and CDK4/6 inhibitor therapy grows, elacestrant offers a promising targeted option for patients with ESR1 mutations driving treatment failure.
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
WHO Global Report on Antimicrobial Resistance Sheds Light on Growing Threat
4
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
5
